Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by maysteeler23on Feb 01, 2021 5:28pm
154 Views
Post# 32440504

RE:RE:RE:RE:RE:RE:GME is a joke. MMED is a revolution. Let’s squeeze

RE:RE:RE:RE:RE:RE:GME is a joke. MMED is a revolution. Let’s squeeze

The shorts at GME got into trouble as the price 2x from $20. From Jan12-jan19 the 2x happened.  Consolidated for a day and  triggered the margin calls, suffocating the hopes of the shorts,  forcing the shorts to sell to obscene asks.


In MMED just a 2x would start the margin calls and since this stock is thinly traded- putting up $30 ASKS after the double, will raise the price quickly.

At 35% short borrow rate the dominos will fall quickly.  I see $30 in a day after the margin calls kick in.  If you get a tsunami on the US MMEDF side. $100 isn't out of the equation.

This is a neat experiment, one for the record books.  Let's see what happens when a nuke gets blown on the OTC.

The NASDAQ LISTING is coming.  Get ready.

<< Previous
Bullboard Posts
Next >>